2024/12/06 22:00:00 | |
---|---|
Price | |
92.13 USD | |
Difference | -1.35% (-1.26) |
ISIN | US3755581036 |
Symbol | GILD |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 108,469 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 92.00 USD (100) |
Ask (Ask size) | 92.13 USD (700) |
Open | 93.50 USD |
High | 94.218 USD |
Low | 92.03 USD |
Close (prev. day) | 93.39 USD |
VWAP | 92.443688 USD |
Volume (pcs) | 4,470,730 |
Trading volume | 413,439,837.10 |
Number of trades | 52,530 |
Last size | - |
Related Futures | 15 |
Related Options | - |
Date | Headline | Download | |
2024/11/26 | Global Equity Ratings | ||
2024/11/19 | Global Equity Ratings | ||
2024/11/05 | Global Equity Ratings | ||
2024/10/29 | Global Equity Ratings | ||
2024/10/22 | Global Equity Ratings |
2024/12/06 22:00:00 | |
---|---|
Price | |
92.13 USD | |
Difference | -1.35% (-1.26) |
ISIN | US3755581036 |
Symbol | GILD |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 108,469 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 92.00 USD (100) |
Ask (Ask size) | 92.13 USD (700) |
Open | 93.50 USD |
High | 94.218 USD |
Low | 92.03 USD |
Close (prev. day) | 93.39 USD |
VWAP | 92.443688 USD |
Volume (pcs) | 4,470,730 |
Trading volume | 413,439,837.10 |
Number of trades | 52,530 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | +48.79% | +18.29% | +41.66% |
Perf (abs.) | +28.61 | +13.49 | +25.66 |
Beta | 0.07 | 0.12 | 0.43 |
Volatility | 26.33 | 25.70 | 23.86 |
Ø price 5 days | Ø volume 5 days (pcs.) | 92.72 USD (7,315,905) |
Ø price 30 days | Ø volume 30 days (pcs.) | 91.28 USD (7,208,271) |
Ø price 100 days | Ø volume 100 days (pcs.) | 83.37 USD (6,512,823) |
Ø price 250 days | Ø volume 250 days (pcs.) | 76.75 USD (7,044,640) |
YTD High | date | 98.90 USD (2024/11/11) |
YTD Low | date | 62.07 USD (2024/05/31) |
52 Weeks High | date | 98.90 USD (2024/11/11) |
52 Weeks Low | date | 62.07 USD (2024/05/31) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/12/06 | 17:35 | 87.61 EUR | 0.12 | 26 |
Vienna Stock Exchange | 2024/12/06 | 17:32 | 87.67 EUR | 0.00 | 5 |
Tradegate | 2024/12/06 | 22:26 | 87.18 EUR | 0.17 | 38 |
Stuttgart | 2024/12/06 | 20:24 | 87.51 EUR | 0.00 | 5 |
SIX Swiss Exchange | 2022/11/02 | 17:36 | 79.50 CHF | 0.00 | 1 |
SIX Swiss Exchange | 2020/04/17 | 17:35 | 85.00 USD | 0.00 | 1 |
Nasdaq | 2024/12/06 | 22:00 | 92.13 USD | 413.44 | 52,530 |
Munich | 2024/12/06 | 08:05 | 88.22 EUR | 0.00 | 2 |
Hanover | 2024/12/06 | 17:25 | 87.64 EUR | 0.00 | 4 |
Hamburg | 2024/12/06 | 17:25 | 87.64 EUR | 0.00 | 4 |
Frankfurt | 2024/12/06 | 15:11 | 88.27 EUR | 0.04 | 3 |
Euronext Milan MTF Trading After Hours | 2024/11/27 | 19:46 | 87.83 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/12/06 | 17:44 | 87.59 EUR | 0.01 | 3 |
Duesseldorf | 2024/12/06 | 19:30 | 87.43 EUR | 0.00 | 7 |
Berlin | 2024/12/06 | 08:08 | 88.18 EUR | 0.00 | 2 |
GILEAD SCIENCES INC. |
- - |
333 Lakeside Drive - 94404 Foster City |
Telefon: +1-650-574-3000 |
Fax: +1-650-522-5853 |
E-mail: - |
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. |
Jacqueline Barton | Member of Board of Directors |
Jeffrey Bluestone | Member of Board of Directors |
Sandra Horning | Member of Board of Directors |
Ted Love | Member of Board of Directors |
Anthony Welters | Member of Board of Directors |
Harish M. Manwani | Member of Board of Directors |
Javier Rodriguez | Member of Board of Directors |
Kelly Kramer | Member of Board of Directors |
Daniel O'Day | Chairman of Managing Board |
Andrew Dickinson | Member of Executive Committee |
Deborah H. Telman | Member of Executive Committee |
Flavius Martin | Member of Executive Committee |
Johanna Mercier | Member of Executive Committee |
Jyoti Mehra | Member of Executive Committee |
MD, PhD Merdad Parsey | Member of Executive Committee |
Stacey Ma | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer